Daiichi Eyes First-Line AML Filings For Vanflyta On Positive Data
Overcoming Past Later-Line Setbacks?
Daiichi Sankyo is aiming to overcome past US and EU setbacks for its FLT3 inhibitor Vanflyta with planned filings for first-line AML on the back of positive new Phase III data.
